Related Experiment Video
Updated: Jan 13, 2026
Differentiation of the SH-SY5Y Human Neuroblastoma Cell Line
Published on: February 17, 2016
CDK4/6 inhibitors display a class effect in inducing differentiation of neuroblastoma cells
Kirsty M Ferguson1, Fiona M Y Abou Grealy1, Anna Philpott1,2
1Jeffrey Cheah Biomedical Centre, Cambridge Stem Cell Institute, Cambridge, CB2 0AW, UK.
Background:
Neuroblastoma is the most common extracranial solid tumour in infants and children, accounting for approximately 15% of paediatric cancer mortality. These tumours are unique in that a subset, namely stage MS, frequently undergo spontaneous regression or differentiation. Differentiation therapy, where cancer cells are re-routed back down their correct developmental pathway, is therefore a promising therapeutic avenue. We have previously shown that the CDK4/6 inhibitor palbociclib induces both decreased proliferation and enhanced neuronal differentiation of neuroblastoma cells in vitro. When combined with retinoic acid, already used clinically for maintenance therapy, this differentiation is enhanced.
Methods:
Here, we investigate two additional CDK4/6 inhibitors, abemaciclib and ribociclib, to induce differentiation of the relapsed, high-risk MYCN-amplified neuroblastoma cell line SK-N-BE(2)C, with and without retinoic acid. We culture SK-N-BE(2)C cells in both adherent and three-dimensional culture and monitor proliferation and differentiation using readouts including live-imaging, immunocytochemistry, qRT-PCR and EdU incorporation.
Results:
We find the CDK4/6 inhibitors palbociclib, abemaciclib and ribociclib all enhance retinoic acid-induced differentiation in both adherent SK-N-BE(2)C cells and 3D spheroids.
Conclusions:
CDK4/6 inhibitors display a class effect in inducing neuronal differentiation together with retinoic acid, both in adherent neuroblastoma cell lines and three-dimensional tumour spheroids. This is an important consideration for potentially developing CDK inhibitor-induced differentiation as a therapy in the clinic.
Insights
Cyclin-dependent kinase (CDK) 4/6 inhibitors, including palbociclib, abemaciclib, and ribociclib, enhance retinoic acid-induced neuroblastoma cell differentiation. This finding supports CDK inhibitor-based differentiation therapy for neuroblastoma.
Area of Science:
- Oncology
- Cell Biology
- Developmental Biology
Background:
- Neuroblastoma is a common pediatric cancer with a subset of tumors undergoing spontaneous regression.
- Differentiation therapy, guiding cancer cells to normal developmental pathways, is a promising strategy.
- Previous research showed palbociclib (a CDK4/6 inhibitor) promotes neuroblastoma cell differentiation and proliferation reduction, enhanced by retinoic acid.
Purpose of the Study:
- To investigate the efficacy of additional CDK4/6 inhibitors (abemaciclib, ribociclib) in inducing neuroblastoma cell differentiation.
- To assess the combined effect of these inhibitors with retinoic acid on neuroblastoma cell differentiation.
- To evaluate differentiation in both standard cell culture and advanced 3D spheroid models.
Main Methods:
- Utilized the relapsed, high-risk MYCN-amplified neuroblastoma cell line SK-N-BE(2)C.
- Cultured cells in both adherent and three-dimensional (3D) spheroid formats.
- Monitored proliferation and differentiation using live-imaging, immunocytochemistry, qRT-PCR, and EdU incorporation assays.
Main Results:
- All tested CDK4/6 inhibitors (palbociclib, abemaciclib, ribociclib) significantly enhanced retinoic acid-induced neuronal differentiation.
- This enhancement was observed in both adherent SK-N-BE(2)C cells and 3D tumor spheroids.
- CDK4/6 inhibitors demonstrated a class effect in promoting differentiation.
Conclusions:
- CDK4/6 inhibitors, in combination with retinoic acid, effectively induce neuronal differentiation in neuroblastoma cells.
- The observed class effect suggests a broader therapeutic potential for CDK inhibitors in neuroblastoma differentiation therapy.
- These findings hold significant implications for developing novel clinical strategies targeting neuroblastoma.
More Related Videos
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
12:17Initiating Differentiation in Immortalized Multipotent Otic Progenitor Cells
Published on: January 2, 2016
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...